MA48027B1 - Composé macrocyclique et utilisations de celui-ci - Google Patents

Composé macrocyclique et utilisations de celui-ci

Info

Publication number
MA48027B1
MA48027B1 MA48027A MA48027A MA48027B1 MA 48027 B1 MA48027 B1 MA 48027B1 MA 48027 A MA48027 A MA 48027A MA 48027 A MA48027 A MA 48027A MA 48027 B1 MA48027 B1 MA 48027B1
Authority
MA
Morocco
Prior art keywords
macrocyclic compound
pharmaceutically acceptable
compound
caf
activity
Prior art date
Application number
MA48027A
Other languages
English (en)
Inventor
Kazunobu Kira
Yoshito Kishi
Ken Ito
Original Assignee
Harvard College
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/814,105 external-priority patent/US9938288B1/en
Application filed by Harvard College, Eisai R&D Man Co Ltd filed Critical Harvard College
Publication of MA48027B1 publication Critical patent/MA48027B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un nouveau composé (1) ayant un effet de remodelage vasculaire tumoral et/ou une activité anti-caf (fibroblastes associés au cancer), ou un sel pharmaceutiquement acceptable de celui-ci, éventuellement dans des utilisations pharmaceutiquement acceptables et médicales de celui-ci. Composé (1)
MA48027A 2017-04-05 2018-04-03 Composé macrocyclique et utilisations de celui-ci MA48027B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762482030P 2017-04-05 2017-04-05
US201762526677P 2017-06-29 2017-06-29
US201762586416P 2017-11-15 2017-11-15
US15/814,105 US9938288B1 (en) 2017-04-05 2017-11-15 Macrocyclic compound and uses thereof
PCT/US2018/025887 WO2018187331A1 (fr) 2017-04-05 2018-04-03 Composé macrocyclique et utilisations correspondantes

Publications (1)

Publication Number Publication Date
MA48027B1 true MA48027B1 (fr) 2022-12-30

Family

ID=63104288

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48027A MA48027B1 (fr) 2017-04-05 2018-04-03 Composé macrocyclique et utilisations de celui-ci

Country Status (33)

Country Link
US (2) US11725015B2 (fr)
EP (2) EP4119563A3 (fr)
JP (4) JP6366873B1 (fr)
KR (2) KR102634732B1 (fr)
CN (2) CN110831946B (fr)
AU (2) AU2018250147B2 (fr)
BR (1) BR112019020208A2 (fr)
CA (1) CA3056945A1 (fr)
CL (1) CL2019002854A1 (fr)
CO (1) CO2019011538A2 (fr)
DK (1) DK3606928T3 (fr)
EC (1) ECSP19075677A (fr)
ES (1) ES2931533T3 (fr)
HR (1) HRP20221385T1 (fr)
HU (1) HUE060466T2 (fr)
IL (2) IL288991B2 (fr)
JO (1) JOP20190234B1 (fr)
LT (1) LT3606928T (fr)
MA (1) MA48027B1 (fr)
MD (1) MD3606928T2 (fr)
MX (1) MX2019011982A (fr)
PE (1) PE20200602A1 (fr)
PH (1) PH12019502197A1 (fr)
PL (1) PL3606928T3 (fr)
PT (1) PT3606928T (fr)
RS (1) RS63755B1 (fr)
SA (1) SA519410259B1 (fr)
SG (1) SG11201908603PA (fr)
SI (1) SI3606928T1 (fr)
TW (1) TWI781163B (fr)
UA (1) UA124399C2 (fr)
WO (1) WO2018187331A1 (fr)
ZA (1) ZA201906279B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3160970A4 (fr) 2014-06-30 2017-12-27 President and Fellows of Harvard College Synthèse d'analogues d'halochondrines et leurs utilisations
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
SG11201908603PA (en) 2017-04-05 2019-10-30 Harvard College Macrocyclic compound and uses thereof
US11548898B2 (en) 2017-07-06 2023-01-10 President And Fellows Of Harvard College Synthesis of halichondrins
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
EP3710454B1 (fr) * 2017-11-15 2024-01-03 President And Fellows Of Harvard College Composés macrocycliques et utilisations de ceux-ci

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK187280A (da) 1980-04-30 1981-10-31 Novo Industri As Ruhedsreducerende middel til et fuldvaskemiddel fuldvaskemiddel og fuldvaskemetode
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
DE4229425A1 (de) 1992-09-03 1994-03-10 Kodak Ag Vorrichtung zum stapelweisen Ablegen und Ausrichten von einzeln zugeführten Blättern
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
US5352804A (en) * 1993-01-19 1994-10-04 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 2
JP2818381B2 (ja) 1994-01-18 1998-10-30 帝人株式会社 ７−チアプロスタグランジン類およびその製造法
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
EP2272839B1 (fr) 1998-06-17 2012-08-22 Eisai R&D Management Co., Ltd. Intermédiaires pour la préparation d'analogues d'halichondrine
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
JP2001305734A (ja) 2000-04-20 2001-11-02 Fuji Photo Film Co Ltd 光重合性組成物
JP2003261447A (ja) 2002-03-07 2003-09-16 Kyosei Seiyaku Kk 抗腫瘍剤
PL2522663T3 (pl) 2004-06-03 2015-08-31 Eisai R&D Man Co Ltd Produkty pośrednie do otrzymywania halichondryny B
JP2008522623A (ja) 2004-12-09 2008-07-03 エーザイ株式会社 ハリコンドリンｂアナログを使用した癌治療でのチューブリンアイソタイプのスクリーニング
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
RU2424622C2 (ru) 2007-03-07 2011-07-20 Интердиджитал Текнолоджи Корпорейшн СПОСОБ И УСТРОЙСТВО ДЛЯ ФОРМИРОВАНИЯ И ОБРАБОТКИ ПРОТОКОЛЬНОГО БЛОКА ДАННЫХ MAC-ehs
WO2008157490A1 (fr) 2007-06-18 2008-12-24 Medimmune, Llc Traitement synergique de cellules qui expriment epha2 et erbb2
MX2010003599A (es) 2007-10-03 2010-09-10 Eisai R&D Man Co Ltd Intermediarios y metodos para la sintesis de analogos de halicondrina b.
BRPI0820519A2 (pt) 2007-11-16 2017-05-23 Eisai R&D Man Co Ltd intermediário para a síntese do análogo de halicondrina b e reação de dessulfonilação usada para o intermediário
CN105801599A (zh) 2008-04-04 2016-07-27 卫材R&D管理有限公司 软海绵素b类似物
BR112012018232B8 (pt) 2010-01-26 2023-01-10 Eisai R&D Man Co Ltd Compostos derivados de furo [3,2-b] pirano úteis na síntese de análogos de halicondrina b e métodos de sintetização de er-80402 e de eribulina
US9079952B2 (en) 2011-01-10 2015-07-14 President And Fellows Of Harvard College Method for delivering agents into cells using bacterial toxins
WO2012147900A1 (fr) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Procédé en microréacteurs pour synthèse d'analogue d'halichondrine b
CA2857395A1 (fr) 2011-12-16 2013-06-20 Alphora Research Inc. Procede de preparation de derives de 3-((2s,5s)-4-methylene-5- (3-oxopropyl)tetrahydrofuran-2-yl)propanol et d'intermediaires utiles a leur preparation
CA2860446C (fr) 2011-12-29 2017-01-10 Alphora Research Inc. Derives de 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofurane-2-yl)acetaldehyde et procede pour leur preparation
WO2013142999A1 (fr) 2012-03-30 2013-10-03 Alphora Research Inc. Procédé de synthèse pour la préparation d'analogues c1-céto macrocycliques de l'halichondrine b et intermédiaires utiles dans celui-ci
WO2014082286A1 (fr) * 2012-11-30 2014-06-05 Hangzhou Zylox Pharma Co., Ltd. Analogue de la rapamycine et procédés de fabrication associés
WO2014183211A1 (fr) 2013-05-15 2014-11-20 Alphora Research Inc. Dérivés de 3-((2s,5s)-4-méthylène-5-(3-oxopropyl)tétrahydrofuran-2-yl)propanol, leur préparation et intermédiaires utiles correspondants
US9850254B2 (en) 2013-07-03 2017-12-26 Sandoz Ag Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing-SO2-(p-tolyl) groups
CA2929084C (fr) * 2013-11-04 2022-01-11 Eisai R&D Management Co., Ltd. Reactions et intermediaires de macrocyclisation et autres fragments utiles dans la synthese d'analogues d'halichondrin b
EP3077399B1 (fr) 2013-12-06 2019-02-20 Eisai R&D Management Co., Ltd. Procédés utiles pour la synthèse d'analogues d'halichondrine b
EP3160970A4 (fr) * 2014-06-30 2017-12-27 President and Fellows of Harvard College Synthèse d'analogues d'halochondrines et leurs utilisations
US10208058B2 (en) 2014-09-09 2019-02-19 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
MX2017014237A (es) 2015-05-07 2018-09-17 Eisai R&D Man Co Ltd Reacciones de macro-ciclizacion e intermediarios y otros fragmentos utiles en la sintesis de macrolidos de halicondrina.
AU2017225982B2 (en) 2016-03-02 2023-10-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
SG11201907217RA (en) 2017-02-20 2019-09-27 Polyphor Ag Pharmaceutical combinations for treating cancer
SG11201908603PA (en) 2017-04-05 2019-10-30 Harvard College Macrocyclic compound and uses thereof
US9938288B1 (en) * 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
WO2019009956A1 (fr) 2017-07-06 2019-01-10 President And Fellows Of Harvard College Synthèse de cétone médiée par fe/cu
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US11548898B2 (en) 2017-07-06 2023-01-10 President And Fellows Of Harvard College Synthesis of halichondrins
EP3710454B1 (fr) 2017-11-15 2024-01-03 President And Fellows Of Harvard College Composés macrocycliques et utilisations de ceux-ci

Also Published As

Publication number Publication date
IL269788A (en) 2019-11-28
LT3606928T (lt) 2022-12-12
US11725015B2 (en) 2023-08-15
PE20200602A1 (es) 2020-03-10
WO2018187331A8 (fr) 2018-12-06
AU2022291454A1 (en) 2023-02-16
HUE060466T2 (hu) 2023-03-28
ECSP19075677A (es) 2020-01-31
DK3606928T3 (da) 2022-11-28
IL288991A (en) 2022-02-01
CN115093429A (zh) 2022-09-23
MD3606928T2 (ro) 2022-12-31
JOP20190234B1 (ar) 2023-09-17
JP2022153392A (ja) 2022-10-12
ES2931533T3 (es) 2022-12-30
TWI781163B (zh) 2022-10-21
KR20240023674A (ko) 2024-02-22
PL3606928T3 (pl) 2023-02-06
SA519410259B1 (ar) 2022-09-11
TW202321259A (zh) 2023-06-01
US20230406863A1 (en) 2023-12-21
KR20190137121A (ko) 2019-12-10
US20210261566A1 (en) 2021-08-26
CN110831946B (zh) 2022-06-21
WO2018187331A1 (fr) 2018-10-11
EP3606928A1 (fr) 2020-02-12
EP4119563A2 (fr) 2023-01-18
SI3606928T1 (sl) 2023-02-28
PH12019502197A1 (en) 2020-12-07
EP3606928B1 (fr) 2022-09-07
PT3606928T (pt) 2022-12-05
JOP20190234A1 (ar) 2019-10-03
RU2019135531A3 (fr) 2021-09-07
JP2018177774A (ja) 2018-11-15
UA124399C2 (uk) 2021-09-08
TW201902902A (zh) 2019-01-16
RS63755B1 (sr) 2022-12-30
JP2024028872A (ja) 2024-03-05
CL2019002854A1 (es) 2019-12-27
AU2018250147B2 (en) 2022-09-29
JP7400025B2 (ja) 2023-12-18
KR102634732B1 (ko) 2024-02-13
AU2018250147A1 (en) 2019-10-03
MX2019011982A (es) 2019-11-08
BR112019020208A2 (pt) 2020-04-22
IL288991B2 (en) 2023-12-01
JP2020513021A (ja) 2020-04-30
CO2019011538A2 (es) 2020-02-28
JP7168580B2 (ja) 2022-11-09
IL288991B1 (en) 2023-08-01
CN110831946A (zh) 2020-02-21
JP6366873B1 (ja) 2018-08-08
IL269788B (en) 2022-01-01
HRP20221385T1 (hr) 2023-01-06
AU2022291454B2 (en) 2024-03-28
EP4119563A3 (fr) 2023-04-05
ZA201906279B (en) 2021-01-27
RU2019135531A (ru) 2021-05-05
SG11201908603PA (en) 2019-10-30
CA3056945A1 (fr) 2018-10-11

Similar Documents

Publication Publication Date Title
MA48027B1 (fr) Composé macrocyclique et utilisations de celui-ci
EA201990643A1 (ru) Фармацевтические соединения
JOP20190186A1 (ar) مركب كينازولين
MX2023010043A (es) Moduladores del receptor de androgenos y metodos para su uso.
MX2020011528A (es) Inhibidores heterociclicos sustituidos de ptpn11.
EP4302835A3 (fr) Méthodes de traitement du cancer de l'ovaire
MA46337B1 (fr) Composé de pyridine
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
EA201991884A3 (ru) Ингибиторы g12c kras
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
SG11201906435SA (en) Pyrimidine compound and pharmaceutical use thereof
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA201990567A1 (ru) Комбинированная терапия с ингибиторами глутаминазы
MX2020005659A (es) Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia.
CY1124907T1 (el) Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
EA202191358A1 (ru) Новые соединения и их применение в лечении
EA201390499A1 (ru) Соединения, подходящие для ингибирования снк1
EA201892631A1 (ru) Дигидротестостерон и производные и промоторы дигидротестостерона в лечении рака
MX2021009717A (es) Sulfonamidas biciclicas.
EA201892698A1 (ru) Производные пиразолиламинобензимидазола в качестве ингибиторов jak
MX2019005504A (es) Potenciadores de bmp.
EA202091821A1 (ru) Ингибиторы cd73
AR111357A1 (es) Compuestos macrocíclico y sus usos
WO2015057737A3 (fr) Compositions et méthodes de traitement des cancers liés à vprbp